Janux Therapeutics Inc (JANX)vsRevolution Medicines Inc (RVMD)
JANX
Janux Therapeutics Inc
$14.34
-2.91%
HEALTHCARE · Cap: $826.95M
RVMD
Revolution Medicines Inc
$165.81
+0.15%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Janux Therapeutics Inc generates 1751% more annual revenue ($13.73M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. JANX earns a higher WallStSmart Score of 40/100 (D).
JANX
Hold40
out of 100
Grade: D
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+81.7%
Fair Value
$71.70
Current Price
$14.34
$57.36 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 2178.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JANX
The strongest argument for JANX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 2178.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : JANX
The primary concerns for JANX are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
JANX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
JANX carries more volatility with a beta of 2.52 — expect wider price swings.
JANX is growing revenue faster at 2178.0% — sustainability is the question.
JANX generates stronger free cash flow (-13M), providing more financial flexibility.
Bottom Line
JANX scores higher overall (40/100 vs 24/100) and 2178.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Janux Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?